Pharma BD Deal Intelligence
Sun Pharma announced Caraco's definitive agreement to buy URL Pharma's generics business from Takeda, expanding Sun's US oral-solids footprint.
Sun Pharma's subsidiary Caraco agreed to acquire the non-Colcrys generics business of URL Pharma, enhancing Sun's U.S. portfolio with over 100 products…
Takeda sold its URL Pharma generic business, excluding Colcrys, to Sun Pharma's Caraco unit six months after its $800 million URL acquisition. Financial…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Sun Pharma acquired URL Pharma's non-Colcrys generic business from Takeda following Takeda's $800M URL acquisition. Provided Sun with US generics portfolio expansion. Financial terms partially disclosed.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. / URL Pharma, Inc. (generics business) (this deal) | 2012 | $60M | 34 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2014 | $4.0B | 66 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2015 | $4.0B | 52 |
| Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc. | 2012 | $230M | 49 |
| Sun Pharmaceutical Industries Ltd. / Organon & Co. | 2026 | $11.8B | — |
| Sun Pharmaceutical Industries Ltd. / Checkpoint Therapeutics, Inc. | 2025 | $355M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
← Browse all deals · How we score deals
More: 2012 deals · Sun Pharmaceutical Industries Ltd. deals · Other deals